Your browser doesn't support javascript.
loading
Widespread xanthomas regression by personalized lipid lowering therapy in heterozygous familial hypercholesterolemia / Regresión generalizada de xantomas mediante terapia hipolipemiante personalizada en hipercolesterolemia familiar heterocigótica
Sbrana, Francesco; Dal Pino, Beatrice; Bigazzi, Federico; Sampietro, Tiziana.
Affiliation
  • Sbrana, Francesco; Fondazione Toscana “Gabriele Monasterio”. Reference Center for Diagnosis and Treatment of Inherited Dyslipidemias. Lipoapheresis Unit. Pisa. Italy
  • Dal Pino, Beatrice; Fondazione Toscana “Gabriele Monasterio”. Reference Center for Diagnosis and Treatment of Inherited Dyslipidemias. Lipoapheresis Unit. Pisa. Italy
  • Bigazzi, Federico; Fondazione Toscana “Gabriele Monasterio”. Reference Center for Diagnosis and Treatment of Inherited Dyslipidemias. Lipoapheresis Unit. Pisa. Italy
  • Sampietro, Tiziana; Fondazione Toscana “Gabriele Monasterio”. Reference Center for Diagnosis and Treatment of Inherited Dyslipidemias. Lipoapheresis Unit. Pisa. Italy
Clín. investig. arterioscler. (Ed. impr.) ; 36(1): 35-37, Ene. -Feb. 2024. ilus, tab
Article in English | IBECS | ID: ibc-230452
Responsible library: ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
“The lower, the better” is the recommended approach in the management of high LDL cholesterol. Unfortunately, this does not always achieve as in the case of a 69-year-old woman referred to our Institute for her lipid profile (LDL cholesterol 412mg/dl), bilateral xanthelasma and cutaneous xanthomas. With a maximized and personalized lipid-lowering therapies (rosuvastatin, ezetimibe, PCSK9i and lipoprotein apheresis), after only six months, the patient showed an impressive regression in her cutaneous xanthomas. (AU)
RESUMEN
«Cuanto más bajo, mejor» es el enfoque recomendado en el tratamiento del colesterol LDL alto. Lamentablemente esto no siempre se logra como en el caso de una mujer de 69 años remitida a nuestro Instituto por su perfil lipídico (colesterol LDL 412 mg/dL), xantelasma bilateral y xantomas cutáneos. Con terapias hipolipemiantes maximizadas y personalizadas (rosuvastatina, ezetimiba, iPCSK9 y aféresis de lipoproteínas), después de solo seis meses, la paciente mostró una regresión impresionante en sus xantomas cutáneos. (AU)
Subject(s)

Search on Google
Collection: National databases / Spain Database: IBECS Main subject: Xanthomatosis / Hyperlipoproteinemia Type II / Hypolipidemic Agents Limits: Aged / Female / Humans Language: English Journal: Clín. investig. arterioscler. (Ed. impr.) Year: 2024 Document type: Article Institution/Affiliation country: Fondazione Toscana “Gabriele Monasterio”/Italy
Search on Google
Collection: National databases / Spain Database: IBECS Main subject: Xanthomatosis / Hyperlipoproteinemia Type II / Hypolipidemic Agents Limits: Aged / Female / Humans Language: English Journal: Clín. investig. arterioscler. (Ed. impr.) Year: 2024 Document type: Article Institution/Affiliation country: Fondazione Toscana “Gabriele Monasterio”/Italy
...